Select Page

5 AI Companies Using Epidemiology to Fight Coronavirus

Apr 1, 2020 | Blog | 0 comments

Daniel Gigante

In the AI vs COVID-19 battle there are three major areas where breakthroughs are needed, coming and have arrived: diagnosis, treatment and epidemiology. In this post, we focus on five companies who are using epidemiology to aid researchers and the general public in the fight against COVID-19.

1. Qventus – Qventus is an AI-based software platform that optimizes patient flow across the hospital including emergency departments and inpatient units. With respect to COVID-19, Qventus helps in two ways (1) with a free epidemiological model that predicts COVID cases and capacity of key resources at a local (metropolitan) level on a daily basis; and (2) with AI-based interventions for COVID command centers, which provide leaders with situational awareness across the health system and allow them to optimize usage of critical resources such as Med-Surg beds, ICU beds, negative airflow isolation rooms, and ventilators.

2. AgileMD – AgileMD offers a mobile-optimized platform that delivers clinical manuals, protocols, and policies for point-of-care use. With respect to COVID-19, they’ve successfully deployed clinical pathways for inpatient, ambulatory, and the emergency room workflows within the electronic health record. They’re currently offering their software and services free to any compatible hospitals facing COVID-19.

3. Akido Labs – Akido Labs partners with large healthcare organizations to help them harness and leverage the power of their data. They’re providing emergency services coordination, disease surveillance, stress monitoring, and testing coordination as part of their COVID-19 response program.

4. Traces – Traces utilizes artificial intelligence to analyze video using 2000 different attributes of a person, except their face. The team feels their software can be used to trace who came into close proximity with those diagnosed. They’re currently offering their product free of charge, to existing customers.

5. Biobot – Biobot develops technology to transform sewers into public health observatories. Their plan is to analyze sewage samples from more than 100 cities across the country with the goal of figuring out how many people have contracted the coronavirus and how quickly it’s spreading.

This list is far from exhaustive, but we hope it provides some insight into the amazing work some companies are doing in the fight against coronavirus.


Submit a Comment

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

‘Life Science Leader’ publishes EVQLV CEO’s Guide for “Demystifying AI”

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

EVQLV, Manhattan BioSolutions Announce UB CAT Grant Award

University at Buffalo Center for Advanced Technology in Big Data and Health Sciences New York City, New York Jun 29, 2021 (  - EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and...

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...